| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9020819 | Vascular Pharmacology | 2005 | 4 Pages |
Abstract
Existence of a 'ceiling effect' is supported by these data. The magnitude of the treatment effect and statistical power when using 6MW as the endpoint. Comparisons between PAH trials that do not adjust for the effects of differing enrollment criteria require caution.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Adaani E. Frost, D. Langleben, R. Oudiz, N. Hill, E. Horn, V. McLaughlin, I.M. Robbins, S. Shapiro, V.F. Tapson, D. Zwicke, T. DeMarco, R. Schilz, M. Rubenfire, R.J. Barst, for the STRIDE-1 Study Group for the STRIDE-1 Study Group,